Gudarz Davar

Dr. Gudarz Davar is the Executive Vice President and Head of Research and Development at Acadia. Dr. Davar is responsible for leading research and development activities and serves as a member of the company’s Executive Management Committee. Dr. Davar joined Acadia from Eli Lilly where he was Vice President, Head of Global Neurology Clinical Development, the senior leadership role responsible for the global development of all neuroscience and core Lilly biomedicines assets through clinical testing and life of the product. Dr. Davar led the global approvals of Emgality® for migraine prevention and US approval for the treatment of cluster headache, as well as the US approval of REYVOW® as a first-in-class, novel, acute treatment for migraine. Prior to Eli Lilly, he served in senior leadership roles in neurology and clinical development at Allergan, Biogen Idec and Amgen. At Allergan, he led a global research and development and commercialization partnership focused on cognitive impairment and neurobehavioral symptoms in Alzheimer’s disease. Dr. Davar received his medical degree from Dalhousie University in Halifax, Nova Scotia. He completed his residency at University of Michigan Hospitals, Ann Arbor, Michigan and is board certified in Neurology.